Regenerex Pharma (RGPX) Cash from Operations (2011 - 2025)

Regenerex Pharma (RGPX) has 13 years of Cash from Operations data on file, last reported at 519355.0 in Q3 2025.

• Cash from Operations for Q3 2025 came in at 519355.0, down 310.21% year-over-year; the trailing twelve-month figure through Sep 2025 was 2440711.0 (down 605.0% YoY), and the FY2025 annual result was 1625351.0, down 255.23% from the prior year.
• Cash from Operations eased to 519355.0 in Q3 2025 per RGPX's latest filing, from 477943.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 1362.0 in Q1 2022 and troughed at 1284700.0 in Q1 2025.
• A 5-year average of 178931.83 and a median of 59883.5 in 2024 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations soared 66.56% in 2022, then sank 2030.79% in 2024.
• A 5-year view of Cash from Operations shows it stood at 17593.0 in 2021, then sank by 62.72% to 28628.0 in 2022, then sank by 248.7% to 99827.0 in 2023, then plunged by 58.99% to 158713.0 in 2024, then slumped by 227.23% to 519355.0 in 2025.
• Business Quant data shows RGPX's Cash from Operations at 519355.0 in Q3 2025, 477943.0 in Q2 2025, and 1284700.0 in Q1 2025.